3 Quantum Computing Stocks Down Sharply -- but 1 Offers Exceptional Value

IonQ reported Q1 revenue of $64.7 million, up 755% year over year, raised full-year guidance to $260 million-$270 million, and ended with a $470 million backlog, but the stock still trades near $57 after a 21% weekly drop. D-Wave posted only $2.9 million of Q1 revenue, but bookings surged to $33.4 million, up 1,994% year over year, with a $20 million system sale and a $10 million enterprise cloud deal supporting second-half 2026 revenue. Rigetti remains earlier-stage at $4.4 million in Q1 revenue, though it has over $569 million in cash and a 108-qubit system sale, underscoring the article's valuation reset across quantum stocks.

Analysis

The key market dynamic is not “quantum is broken,” but that the sector has shifted from narrative beta to execution beta. That matters because the first-order beneficiaries of any re-rating are the names with the clearest conversion of backlog into revenue; the second-order losers are the companies whose valuations still assume optionality without visible monetization. In that framing, the public market is rewarding proof of demand but punishing any gap between technical progress and commercial scale.

IONQ is the cleanest business, but it is also the most crowded consensus long in the group. The more important implication is that its rich multiple can now act as a ceiling on the whole category: every strong print from IONQ raises the bar for QBTS and RGTI, because investors will benchmark all three against a single “best-in-class” leader rather than valuing them on separate milestones. If IONQ’s stock stays heavy, it likely forces capital rotation into cheaper commercial proxies rather than a broad sector melt-up.

QBTS is the asymmetric setup because the market is still pricing it like a science project while bookings suggest a pipeline that could convert with a lag. The second-order effect is that enterprise adoption may be arriving through optimization use cases first, which lowers the dependency on fault-tolerant breakthroughs and broadens the buyer base beyond R&D budgets. The main risk is timing: if second-half revenue conversion slips, the stock can de-rate quickly because the bull case is front-loaded on credibility, not long-duration growth.

RGTI remains the weakest risk/reward: enough cash to survive, not enough commercial proof to underwrite the equity. A large cash balance reduces dilution risk, but it also delays the day when the market can force a true fundamental valuation reset, so the stock can remain “story expensive” longer than bears expect. The contrarian read is that the market may be underestimating how fast QBTS can become the default value name in the sector if enterprise bookings keep compounding.

Key Decisions for Investors

• Long QBTS / short IONQ pair trade, 3-6 month horizon: express relative value on commercialization momentum vs premium valuation; target 20-30% spread capture, cut if IONQ re-rates higher on sustained backlog-to-revenue conversion.
• Avoid initiating fresh long RGTI exposure until revenue scales meaningfully above current run-rate; use any squeeze into strength to fade, with a 6-12 month view that cash alone will not support further multiple expansion.
• For event-driven accounts, buy QBTS call spreads 4-6 months out to capture second-half revenue inflection while limiting downside if contract conversion slips; favorable if the market remains skeptical into the next earnings cycle.
• If already long IONQ, trim into strength and rebuild only on a material post-earnings pullback; the stock still has the best fundamentals, but the valuation leaves limited margin for error over the next 1-2 quarters.
• Watch for a sector-wide sympathy bid after any QBTS contract print; that is the best entry window to short the weakest balance of story and scale, which is likely RGTI first and IONQ last.